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Sarcopenia, severe anxiety 
and increased C‑reactive protein 
are associated with severe fatigue 
in patients with inflammatory 
bowel diseases
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Patients with inflammatory bowel disease (IBD) report fatigue more frequently than healthy 
population, but the precise mechanisms underlying its presence are unknown. This study aimed to 
evaluate the prevalence of fatigue in IBD and its relation with potential causative factors. A survey 
on fatigue, depression, anxiety, sleep disorders, and the presence of sarcopenia and malnutrition, 
was sent by email to 244 IBD outpatients of the Gastroenterology Unit of Academic Hospital of 
Padua. Demographics and clinical data, including the levels of fecal calprotectin (FC) and C‑reactive 
protein (CRP), and current pharmacological treatments were obtained from patients’ medical records. 
Ninety‑nine (40.5%) subjects answered the survey. Ninety‑two (92.9%) patients reported fatigue, with 
sixty‑six having mild to moderate fatigue and twenty‑six severe fatigue. Multivariate analysis showed 
that abnormal values of CRP (OR 5.1), severe anxiety (OR 3.7) and sarcopenia (OR 4.4) were the factors 
independently associated with severe fatigue. Fatigue has a high prevalence in subject affected by 
IBD. Subjects with altered CRP, sarcopenia and severe anxiety appear more at risk of severe fatigue.
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic 
inflammatory diseases affecting the gastrointestinal  tract1. IBD is a lifelong condition without a cure, and because 
of the chronicity of symptoms and progression to disability, particularly in CD, patients with IBD may experience 
impaired quality of life, psychological illness, including anxiety and depression, sleep disturbance, and  fatigue2–6. 
Moreover, patients affected by IBD are subjected to a major risk of malabsorption and reduction of food  intake7,8. 
Finally, IBD patients tend to have a sedentary lifestyle, although physical activity is not contraindicated in this 
 population8. All these factors contribute to an increased risk of developing protein energy malnutrition and 
 sarcopenia9.
Fatigue is defined as an “overwhelming sense of tiredness, reduced energy levels and feeling of exhaustion 
that is not responsive to prolonged rest or sleep”7,10. In people affected by IBD, fatigue has been reported by up 
to 80% of patients with active disease and up to 54% of patients in  remission11 twice more common than healthy 
 controls12, and it is commonly defined as the most debilitating symptom during the period of disease  inactivity9,13. 
Fatigue impacts negatively on every day occupations, on concentration during social interaction and causes the 
suspension of physical  activity14. The self-imposed restrictions caused by fatigue elicit feelings of anger, resent-
ment, self-pity and sadness, causing worsening of the quality of life. Causal factors are unknown because of the 
multifactorial nature of the  symptom13. When measured with functional scales, fatigue is more prevalent in 
young women, those who are physically inactive, with a short history of disease, and who declare feeling stressed, 
depressed, or  anxious15–17. Moreover, fatigue has been linked with a sub clinical pro-inflammatory state; it seems 
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in fact that the complex formed by IL-6 and the IL-6 receptor, as well as TNFα, causes a break in the blood–brain 
barrier with effects on the central nervous system, provoking fatigue, anxiety, and  depression18. Corticosteroids 
have been also implicated in the genesis of fatigue, while anti-TNF therapy seems to be  protective19. Finally, 
the presence of micro- or macro-intestinal blood leaks, iron malabsorption, the suppression of erythropoiesis 
and the presence of pro-inflammatory cytokines have been associated with a high prevalence of anemia in IBD, 
partially correlated with the presence of  fatigue11. However, to date, a clear causal relationship between fatigue 
and iron or other micronutrient deficiencies has not been  established9,11,20.
An appealing hypothesis is that fatigue could be due to a reduction in lean mass, a condition caused by a 
combination of malabsorption, chronic inflammation and sedentary  lifestyle8,14,15. Data supporting this theory 
come from the analysis of muscle strength and endurance indices in a sample of IBD patients, which showed a 
significant relation between asthenia and loss of muscle  mass21.
This study aimed to examine the prevalence of fatigue in subject affected by IBD and its relationship with 
sarcopenia and other possible causative factors.
Methods
Study design. The present cross-sectional study was conducted at IBD Unit of Azienda Ospedaliera di 
Padova (Italy). Consecutively and prospectively, all IBD patients who visited our IBD Unit from February to 
July 2020 were asked to participate in this study. The study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research committee of 
Padova University (protocol number 4197/AO/17). Informed consent was obtained from all individual partici-
pants included in the study.
A survey was conducted sending out an email to 244 IBD outpatients. Inclusion criteria were: age over 18, 
a histologically-confirmed diagnosis of CD or UC for a least 6 months, and a recent outpatient encounter with 
the need to perform biochemical assessment of disease activity. Exclusion criteria included the presence of 
known psychiatric disorders, history of alcohol or drug abuse, pregnancy, neoplasia or other systemic disorders 
potentially influencing the psychological status (i.e. connective tissue disorders, fibromyalgia, diabetes mellitus, 
autonomic or peripheral neuropathy, and myopathy), and the lack of consent. Demographics and clinical data, 
including the levels of fecal calprotectin (FC) C-reactive protein (CRP), and current pharmacological treatments 
were obtained from patients’ medical records. For the purpose of the study, active disease was defined by the 
presence of FC values ≥ 250mcg/g and/or a value of Harvey Bradshaw Index > 4 for patients with CD and a partial 
Mayo score > 1 for patients with  UC22,23. Moreover, abnormal CRP was considered when higher than 0.1 mg/dL.
The survey consisted of different questionnaires to be filled after initial formal and written approval of partici-
pation into this study. The time required to complete the questionnaire was approximately 45 min. The domains 
and questionnaires used were:
– Fatigue assessment. To measure fatigue we used the IBD-F questionnaire, specifically developed for IBD 
 patients13,24,25. The questionnaire is composed of two sections: the first examines the presence and the extent 
of fatigue, the second its impact on different aspects of daily  living26. A score from 1 to 10 is suggestive of 
mild to moderate fatigue, a score from 11 to 20 of severe  fatigue25.
– Sarcopenia assessment. Due to SARS-CoV-2 pandemic, we evaluated the presence of sarcopenia only through 
the SARC-F questionnaire, recommended by the European Consensus to elicit the declaration of sarcopenia’s 
signs and  symptoms27. Indeed, there are five SARC-F components: strength, assistance with walking, rising 
from a chair, climbing stairs, and falls. The scores range from 0 to 10, with 0 to 2 points for each component. 
Preliminary studies have suggested that a score equal to or greater than 4 is predictive of sarcopenia and poor 
outcomes.
– Depression and anxiety assessment. Anxiety and depression were assessed via the Hospital Anxiety and 
Depression Scale, a questionnaire validated for epidemiological and clinical  studies28,29, which has been 
demonstrated to be reliable when applied to IBD  patients19. The questionnaire is formed of two scales, each 
one composed of seven items. Normal scores for anxiety or depression are defined by a score less than  830,31. 
A subscore from 8 to 10 is defined as borderline abnormal, and a score from 11 to 21 as  abnormal32.
– Sleep disorders assessment. Sleep quality has been evaluated through the Pittsburgh Sleep Quality Index, a 
questionnaire that examines seven different sleep components: subjective sleep quality, sleep latency, length, 
efficiency, sleep disturbances, drug use and daytime dysfunctions. The sum of each component gives a score 
from 0 to 21. A score of 5 or above suggests poor sleep  quality33.
– Quality of life assessment. Quality of life was measured through the Inflammatory Bowel Disease Question-
naire Short  Form34, specifically developed for testing subjects affected by these pathologies. It is widely 
validated, and has been demonstrated to be reliable and  sensitive35. It is composed of ten questions, a subset 
of the full Inflammatory Bowel Disease Questionnaire, graded on a 7-point Likert scale from 1 (a very 
severe problem) to 7 (not a problem at all)36. A maximum of 70 indicates the best IBD related quality of life, 
a minimum of 10 indicates the  worst36.
– Malnutrition assessment. Malnutrition was diagnosed according to the Global Leadership Initiative on Mal-
nutrition criteria, namely in the presence of a weight loss greater than the 5% within the past 6 months or a 
BMI < 20 if the subject was aged less than 70 years old, or a BMI < 22 if the subject was 70 years old or older, 
and the concomitant presence of active inflammatory disease or an abnormal value of  CRP37.
Statistical analysis. Categorical variables were expressed as frequency and continuous variables as 
mean ± standard deviation (SD). We used univariate logistic regression models to assess whether demographic 
or IBD-related variables, HADS, IBDQ, PSQI, sarcopenia, or malnutrition were related to severe fatigue. Sta-
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tistically significant variables in univariate analyses were then included in a multivariate regression model to 
identify, using the AIC stepwise method, independent risk factors for fatigue. A p-value < 0.05 was considered 
statistically significant. STATA 11 software was used to perform statistical analysis.
Ethics committee approval. The study protocol conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki as reflected in a priori approval by the institution’s human research committee of Padova Uni-
versity, Italy (protocol number 4197/AO/17).
Informed consent. Informed consent was obtained from all individual participants included in the study.
Results
Characteristics of study participants. Ninety-nine out of 244 (40.5%) IBD outpatients followed at our 
IBD unit and enrolled in the study, answered the survey by email. Table 1 summarizes the main demographic 
and clinical characteristics of the study population. The mean age of subjects was 38.7 ± 13.9 years, there were 
57.5% males and 54.5% patients affected by CD. Almost 50% had a duration of disease longer than 10 years. 
Among the entire population, 30% had clinically and/or biochemically active disease, 44% were taking biological 
therapies, and only 3% were on a corticosteroid.
Sarcopenia and malnutrition. According to the SARC-F questionnaire, 13 subjects were sarcopenic 
(13.1%), with a mean score of 1.4 ± 1.7. Among the participants, 25 were malnourished: 16 satisfied the phe-
notypic criteria showing a BMI < 20 (mean BMI of malnourished subjects with low BMI: 18.2 ± 1.2 kg/m2), and 
nine reported weight loss greater than the 5% in the past 6 months (mean weight loss 8.1 ± 5.8 kg).
Depression, anxiety, sleep disorders and quality of life. After completing the HADS scale, 21 
(21.2%) subjects had borderline abnormal anxiety scores and 32 (32.3%) abnormal anxiety scores, with an over-
all mean score of 7.9 ± 4.4. Twenty subjects had borderline abnormal depression scores and six abnormal depres-
sion scores, with a mean score of 4.9 ± 3.3. A condition of altered sleep quality was found in 62 subjects (62.6%, 
mean score 6.9 ± 6.6). Because of the absence of established cut-offs, scores from IBDQ-SF were divided into 
tertiles obtaining 35 (35.3%) subjects in the first tertile (worst quality of life, score 10–42), 37 (37.3%) subjects in 
the second (score 43–56), and 27 (27.2%) in the third (best quality of life, score 57–70) tertile. The mean IBDQ 
score value was 47.8 ± 13.6.
Table 1.  Demographical and clinical characteristics of the 99 IBD patients who answered the survey.
Features IBD patients (n = 99)




Type of disease, n (%)
Crohn’s disease 54 (54.5%)
Ulcerative Colitis 45 (45.4%)
Disease stage, n (%)
Active 29 (29.2%)
Remission 70 (70.7%)
Duration of disease, n (%)
< 5 years 28 (28.2%)
5–10 years 22 (22.2%)
> 10 years 49 (49.4%)
Weight, mean ± sd 67.2 ± 13.8
BMI 23.02 ± 3.5
Pharmacological therapy on-going, n (%)
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Fatigue: prevalence, severity and risk factors. The overall prevalence of fatigue in the sample was 
92.9%, out of whom seven (7.1%) patients declared no fatigue, sixty-six (66.6%) had mild-to-moderate fatigue, 
and 26 (26.2%) had severe fatigue (Table 2).
Based on univariate analysis, we observed that patients with severe anxiety, borderline abnormal or abnor-
mal depression scores, low QoL, sleep disturbances, sarcopenia, malnutrition, and abnormal CRP (> 0.1 mg/
dL) were more likely to report severe fatigue (Table 2). In contrast, age, type of disease, sex, disease duration, 
medical therapies and fecal calprotectin were not associated with fatigue (Table 2). After multivariate regression, 
including all significant risk factors in univariate analysis, only abnormal CRP values (OR 5.1, 95% CI 1.3–20.2), 
severe anxiety (OR 3.7 95% CI 0.93–15) and sarcopenia (OR 4.4, 95% CI 1.1–20.1) were identified as risk factors 
for severe fatigue in IBD patients.
Discussion
Fatigue is a symptom characterized by an overwhelming sense of tiredness unresponsive to rest or sleep and caus-
ing frustration, absenteeism from work, reduction of activities and impairment of social  life13. In subjects with 
IBD, fatigue is more prevalent than in a healthy  population11, and is reported to be one of the worst symptoms 
during disease remission, determining higher levels of intestinal disease worries and  concerns38. Evidences on 
its cause, prevalence and management are still  uncertain39. Thus, this study was performed in order to increase 
our understanding on the prevalence of fatigue in patients with IBD and, at the same time, explore factors that 
might be associated with it. In particular, we evaluated whether muscle mass reduction could play a role in 
Table 2.  Univariate and multivariate analysis aimed to evaluated the risk factors associated to severe fatigue. 
*We merged II and III tertile because only 1 person in the III tertile (best Qol) had severe fatigue.
Variable Subgroups All patients
N (%) of patients with severe 
fatigue Unadjusted OR (95%CI) p value Adjusted OR (95% CI) p value
Age
 < 40 50 14 (28) 1
0.69
 ≥ 40 49 12 (24.4) 0.83 (0.34–2.0)
Sex
Male 57 17 (29.8) 1
0.35
Female 42 9 (21.4) 0.64 (0.25–1.6)
BMI
 < 25 72 21 (29.7) 1
0.28
 ≥ 25 27 5 (18.5) 0.55 (0.18–1.65)
Type of Disease
CD 54 17 (31.4) 1
0.19
UC 45 9 (20) 0.54 (0.21–1.37)
Duration of disease
 < 5 years 28 8 (28.5) 1
0.915–10 years 22 6 (27.2) 0.93 (0.26–3.25)
 > 10 years 49 12 (24.5) 0.81 (0.28–2.31)
Biologic therapies
No 55 16 (29) 1
0.23
Yes 44 10 (22) 0.6 (0.2–1.43)
Steroid therapies
No 96 25 (26) 1
0.77
Yes 3 1 (33) 1.4 (0.1–16.3)
Anxiety
Absent 46 6 (13) 1 0.7 1 0.9




Severe 32 16 (50) 6.17 (2–18.6) 3.7 (0.9–15)
Depression
Absent 73 13 (17.8) 1
Mild/moderate 20 10 (50) 4.6 (1.5–13.3) 0.004
Severe 6 3 (50) 6.9 (1–45.7) 0.5
Sleep
Normal 37 4 (10.8) 1
0.002
Altered 62 22 (35.4) 5.2 (1.7–15.5)
Malnutrition
No 74 15 (20.3) 1
0.02
Yes 25 11 (44) 3.09 (1.1–8.1)
IBDQ score
Better Qol
(II and III tertiles) 64 9 (14)* 1
< 0.001
Worst Qol
(I tertile) 35 17 (48) 6.22 (2.3–16.4)
Sarcopenia




Yes 13 9 (69.2) 9.1 (2.5–33.2) 4.8 (1.1–20.1)
Fecal Calprotectin (≥ 250 ug/dl)
Normal 70 15 (21.4) 1
0.09
Pathologic 29 11 (37.9) 2.4 (0.9–5.7)
CRP (> 0,1 mg/dL)




Pathologic 16 8 (50) 3.6 (1.18–10.9) 5.1 (1.3 – 20.2)
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determining fatigue, in addition to the previously mentioned features. The results of our analysis show a high 
prevalence of fatigue in patients affected by IBD, represented by a sample composed mainly of young people 
with a long history of disease. We did not find any influence of sex, age, or disease duration on fatigue, whereas 
we found that fatigue was associated with altered CRP, severe anxiety and sarcopenia.
Our study population was mainly composed by young adults (mean age 38.7 ± 13.9 years). Nevertheless, 
despite their young age, the rate of subjects having sarcopenia was relevant. Sarcopenia is considered a relevant 
risk factor for functional age-related negative outcomes, including frailty and disability. Consistently, the parallel 
clinical evolution of sarcopenia and fatigue in such a young sample of patients with IBD may have important 
clinical implication since could represent an early alarm, in the perspective of future aging  trajectories40.
Patients affected by IBD are subjected to a major risk of  malabsorption7. This happens because the intestinal 
mucosa is not fully functional, especially when the disease is more active, because of the possible presence of 
complications such as fistulae, loss of mucosal absorptive surface, bowel resections, and because of the pharma-
cological therapies such as corticosteroids, which cause insulin resistance and leads to loss of calcium, vitamin D, 
albumin, and  immunoglobulins41. Moreover, chronic inflammation and anorexia may increase energy expendi-
ture and food  intake10. In particular, sarcopenia is a condition of reduced muscle mass, strength, and function 
that impacts people affected by CD more than those affected by UC, with an estimated prevalence according to 
the European Society for Clinical Nutrition and Metabolism (ESPEN) of 28% and 13%,  respectively42. The loss of 
lean mass is more prevalent, and happens at younger age, in people affected by IBD than in healthy  individuals43. 
Among our patients, overall prevalence of sarcopenia was 13%, less than that reported in the literature, prob-
ably because of limitations of the SARC-F in detecting severe  sarcopenia27. Nevertheless, its prevalence and 
the association observed following multivariate regression analysis suggest that sarcopenia represents a major 
contributor to fatigue in some patients with IBD.
In contrast to other  authors9,26,34, we did not find a different prevalence of severe fatigue between UC and CD 
or among patients using different pharmacological treatments. This could be due to the fact that in our cohort 
only a few patients were taking corticosteroids, the therapy most often associated with fatigue in previous studies. 
Concerning anti-TNF therapies, adalimumab was reported have no effect on fatigue in a Cochrane meta-analysis 
and data about vedolizumab were too limited to perform any sub-analysis39. Thus, their efficacy in relieving 
fatigue is still questionable, and our study is in line with this  interpretation39. Consistent to what is reported in 
literature, we did not observe that severe fatigue was more frequent in subjects with active IBD (as defined by 
fecal calprotectin), but we found a higher risk in subjects with abnormal CRP, in keeping with the observation 
of higher levels of inflammatory mediators in subjects experiencing fatigue and  depression44.
The study design does not allow to evaluate the inference of a causal relation between sarcopenia and fatigue. 
We can only hypothesize, as proposed in the theoretical framework, that fatigue could be caused by lean mass 
reduction, in turn maybe caused by  malnutrition45, a condition which affected 25% of our sample. On the other 
hand, it is also possible that fatigue perception causes a reduction in physical activity and therefore a reduction 
of muscle mass, sustained by malnutrition. This is the main hypothesis behind a study analyzing the relationship 
between muscle loss and systemic lupus erythematosus—related fatigue in a small sample of patients. The authors 
observed, via MRI, a voluntary reduced muscle contraction in subjects perceiving higher exertion, concluding 
toward a sarcopenia driven by fatigue, rather than the  opposite46. The two interpretations however, instead of 
opposite, could be seen as a self-powered vicious cycle. This finding is consistent with the literature concerning 
strategies to treat fatigue: physical activity has already been identified as a valid therapeutic intervention for dif-
ferent  cancers47–49 and two exploratory studies showed promising effects in subjects affected by  IBD39,50. In the 
first study, investigators prescribed individual advice to increase physical activity by 30%, with some suggestion 
of the efficacy of this  intervention50. In the second study the intervention was composed of three sessions of 
60 min of strength exercises for 26 consecutive weeks, resulting in an improvement in quality of life and lumbar 
bone mineral density, and a decrease of fatigue perception measured with the IBD-F  questionnaire39.
Fatigue resulted significantly related with severe anxiety and borderline abnormal or abnormal depression 
scores, confirming its connection on patient’s mental wellbeing. Subjects experiencing fatigue were more likely 
to have abnormal anxiety and depression scores, sleep disorders and to have lower quality of life scores (whose 
prevalence in our sample was of the 73%). This latter relationship has been described by  others19, and may be 
linked to the burden of living with a chronic  disease38, or even a physiological response to inflammation medi-
ated by  cytokines30. Sleep disturbances are recurrent in subjects affected by IBD also suffering for anxiety and 
 depression5, worsening patients’ quality of  life5,51. Poor sleep quality has already been associated with  fatigue20, 
and the compresence of these two symptoms is considered an alert to deepen not only the presence of psycho-
logical disorder, but also of the gastrointestinal disease  activity51. These two variables, however, lost significance 
in the multivariate analysis. Previous literature described the existence of a bidirectional link between fatigue 
and psychological dysfunctions, indicate as realistic both the hypothesis of fatigue as causative factor and the 
idea that negative feelings, maladaptive behaviors, and negative perception about the symptoms can worsen the 
perception of  it52.
Our multivariate model suggests that sarcopenia, altered CRP and severe anxiety were the only independent 
risk factors for severe fatigue. In particular, we observed that patient with altered CRP and sarcopenia had an 
5.1 and 4.4 higher odds of reporting severe fatigue respectively, while patients with severe anxiety had an 3.7 
higher risk of severe fatigue. This finding is in line with the results of Patino-Hernandez et al., who found, in a 
study performed in an elderly population, that sarcopenia was significantly related to fatigue and depression, 
but when adjusted for confounding, only fatigue was independently related to  it53. The authors explained this 
phenomenon with the overlap of items between depression and fatigue measurement tools. In contrast, Norden 
et al. in a study on fatigue in tumor-bearing mice, observed that the animals developed fatigue and a depressive-
like behavior prior to muscle loss, in this case caused by the presence of the  tumor44. The authors pointed out 
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depressive symptom as the first determinant in developing fatigue, with sarcopenia and the worsening of quality 
of life as the main consequences.
This study has some limits, first of all the diagnosis of sarcopenia was based only on the SARC-F question-
naire. The European Consensus stated clearly about the fact that strength exercises and muscle quantity measures 
represent the gold standard of sarcopenia assessment, and a more accurate study should conduct these proce-
dures. However, due to the restrictions related to the risk of COVID transmission, we reduced access to the hos-
pital for all patients and therefore more objective assessments were not possible. Moreover, the same pandemic 
affected our ability to recruit patients, thus resulting in a limited sample size, together with a lower response rate 
(40.5%) to the survey, as compared with other studies investigating fatigue by means of questionnaire (55%). 
Further, the cross-sectional design of this investigation did not allow us to establish if the presence of severe 
fatigue caused a low sarcopenia or vice versa. Despite the importance of the physical activity, we did not ask 
the patients about this in the survey. Lastly, diagnosis of active disease was not based on objective evidence like 
endoscopy or radiology, but on a fecal calprotectin value, although this is widely accepted as a good biomarker 
of disease activity in patients with  IBD54. Nevertheless, the study suggests a connection between fatigue and 
sarcopenia. What is clear is that when studying a complex phenomenon like fatigue, it cannot be done without 
taking into account both physical and psychological health.
In conclusion, we confirm that fatigue is a symptom with a high prevalence in subjects affected by IBD and 
sarcopenia, a condition caused by malnutrition and the state of chronic inflammation typical of these patients, 
is an important risk factor for it. Moreover, we observed a higher prevalence of severe fatigue in subjects with 
severe anxiety. Thus, subjects affected by IBD should be asked about the presence of fatigue during clinical 
evaluation, above all in case of concomitant symptoms such as anxiety, depression or bad sleep quality, and 
they should eventually be referred to a professional for a consultation. The role of physical activity in protecting 
from fatigue seems promising and should be encouraged, when considered appropriated, because of its role in 
preventing lean mass loss and therefore maintaining individuals’ autonomy, preventing from hospitalization and 
improving quality of life. Further research on the underlying causes of fatigue, as well as effective interventions 
to treat it, are needed.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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